Valo Health, LLC (Valo) is a technology company that is using human-centric data and machine learning-anchored computation to transform the drug discovery and development process. By integrating data across the drug development lifecycle, the discovery and development of life-changing treatments can be accelerated, with the potential to reduce cost, time, and failure rate. The company's Opal Computational Platform™, a fully integrated, componentized, end-to-end drug development platform, offers a unique approach to therapeutic development, that enables Valo to advance a robust pipeline of candidates across cardiovascular disease, oncology, and neurodegeneration.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 01/13/21 | $190,000,000 | Series B |
Atinum Investment Flagship Pioneering  HBM Healthcare Investments Invus Mirae Asset Venture Investment PSP Investments | undisclosed |
| 03/09/21 | $110,000,000 | Series B |
Koch Disruptive Technologies | undisclosed |
